GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 244.4

Change

0.00 (0.00)%

Market Cap

USD 15.09B

Volume

21.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

-0.58 (-1.27%)

USD 432.12B
MATA:F Panasonic Corporation

-0.01 (-5.56%)

USD 20.38B
1CK:F CK Asset Holdings Limited

+0.07 (+2.10%)

USD 12.84B
AD5B:F Adevinta ASA

N/A

USD 12.23B
0PY:F Paycom Soft

-3.55 (-2.63%)

USD 7.88B
KMBA:F SK TELECOM CO.LTD.ADR 5/9

+0.40 (+2.17%)

USD 7.37B
UIPN:F Unipol Gruppo Finanziario Spa

+0.05 (+0.49%)

USD 6.37B
2U4:F HICL Infrastructure PLC

+0.01 (+0.69%)

USD 2.72B
CLN:F The City of London Investment ..

-0.13 (-2.46%)

USD 1.92B
R7I:F RENEWABLES INFRASTRUCTURE

-0.01 (-0.70%)

USD 1.74B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.96% N/A N/A 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.96% N/A N/A 22% F
Trailing 12 Months  
Capital Gain -31.77% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.77% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 52.32% N/A N/A 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.32% N/A N/A 58% F
Average Annual (5 Year Horizon)  
Capital Gain 14.95% N/A N/A 81% B-
Dividend Return 14.95% N/A N/A 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.04% N/A N/A 36% F
Risk Adjusted Return 46.64% N/A N/A 71% C-
Market Capitalization 15.09B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike